Xenon to Present at the 2025 RBC Capital Markets Global Healthcare Conference

Rhea-AI Summary

Xenon Pharmaceuticals (Nasdaq: XENE) announced its participation in the upcoming 2025 RBC Capital Markets Global Healthcare Conference in New York. CEO Ian Mortimer will present a fireside chat on Wednesday, May 21, 2025, from 10:30-10:55 AM ET. The presentation will be available via webcast on Xenon's website.

Xenon is a neuroscience-focused biopharmaceutical company developing ion channel products for epilepsy and depression. Their lead candidate, azetukalner, is a Kv7 potassium channel opener in late-stage clinical development for multiple indications.

News Market Reaction – XENE

-0.57%

-0.57% Session move

In the trading session that priced this news, XENE declined 0.57%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

VANCOUVER, British Columbia and BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the 2025 RBC Capital Markets Global Healthcare Conference taking place in New York, NY from May 20-21, 2025.

Fireside Chat Presentation Details:

Date:  Wednesday, May 21, 2025

Time:  10:30-10:55 AM Eastern Time

Webcast:  Register here

Presenter:  Ian Mortimer, President and Chief Executive Officer

A live audio webcast of the company presentation will be available on the “Investors” section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit www.xenon-pharma.com.

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Contacts:
For Investors:
Chad Fugere
Vice President, Investor Relations
(857) 675-7275
investors@xenon-pharma.com

For Media:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
media@xenon-pharma.com

FAQ

When is Xenon Pharmaceuticals (XENE) presenting at the 2025 RBC Capital Markets Healthcare Conference?

Xenon Pharmaceuticals will present on Wednesday, May 21, 2025, from 10:30-10:55 AM Eastern Time at the RBC Capital Markets Global Healthcare Conference in New York.

Who will be presenting for Xenon Pharmaceuticals (XENE) at the RBC Healthcare Conference?

Ian Mortimer, President and Chief Executive Officer of Xenon Pharmaceuticals, will be presenting the fireside chat.

What is Xenon Pharmaceuticals' (XENE) lead drug candidate?

Azetukalner, a novel Kv7 potassium channel opener, is Xenon's most advanced drug candidate in late-stage clinical development for multiple indications.

What therapeutic areas does Xenon Pharmaceuticals (XENE) focus on?

Xenon Pharmaceuticals focuses on neuroscience, specifically developing ion channel products for epilepsy and depression.